Aclaris Therapeutics (ACRS) Interest & Investment Income (2014 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Interest & Investment Income came in at -$588000.0 in Q1 2026, down 274.48% year-on-year from $337000.0 in Q1 2025, and down 4623.08% quarter-over-quarter from $13000.0 in Q4 2025.
Aclaris Therapeutics (ACRS) Interest & Investment Income (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Interest & Investment Income history runs 13 years deep, the most recent figure standing at -$588000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 274.48% year-over-year to -$588000.0 in Q1 2026; TTM through Mar 2026 was -$412000.0, a 83.86% increase from a year earlier, with the FY2025 full-year figure at $513000.0, up 152.71% from the prior year.
- Interest & Investment Income eased to -$588000.0 in Q1 2026 per ACRS's latest filing, from $13000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.3 million in Q3 2023 and bottomed at -$5.6 million in Q4 2024.
- The 5-year median for Interest & Investment Income is $115000.0 (2025), against an average of $155529.4.
- Across the five-year window, Interest & Investment Income plunged 2880.0% in 2022 and soared 1766.19% in 2023, its largest moves.
- Year by year, Interest & Investment Income stood at $568000.0 in 2022, then jumped by 285.39% to $2.2 million in 2023, then plunged by 357.97% to -$5.6 million in 2024, then surged by 100.23% to $13000.0 in 2025, then slumped by 4623.08% to -$588000.0 in 2026.
- Per Business Quant, the three latest ACRS Interest & Investment Income figures stand at -$588000.0 (Q1 2026), $13000.0 (Q4 2025), and $115000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Aclaris Therapeutics | 672.39 Mn | 672.39 Mn | 1.60 Mn | -588,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -588,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 337,000.00 |
| Dec 31, 2024 | -5.65 Mn |
| Sep 30, 2024 | 890,000.00 |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | -757,000.00 |
| Mar 31, 2023 | 543,000.00 |
| Dec 31, 2022 | 568,000.00 |
| Sep 30, 2022 | -139,000.00 |
| Jun 30, 2022 | -354,000.00 |
| Mar 31, 2022 | -748,000.00 |
| Dec 31, 2021 | -224,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | 25,000.00 |